Monday, August 26, 2019 09:42 AM

ASSESSING THE RELATIONSHIP BETWEEN STATIN USE AND ONCOLOGIC OUTCOMES AMONG MEN ELECTING ACTIVE SURVEILLANCE FOR LOCALIZED PROSTATE CANCER - BEYOND THE ABSTRACT - UROTODAY

There has been an increase in the use of active surveillance (AS) over the last 5-10 years. However, the rate of treatment among men electing AS is approximately 50% at 10-years. This raises the question: is there an intervention that can delay disease progression and/or prevent the need for intervention? One potential therapeutic agent that could be considered are HMG-CoA reductase inhibitorsalso known as statins. Data from most clinical trials demonstrate that statin use, in a dose-dependent manner, is associated with a reduced risk of advanced prostate cancer. However, there is limited evidence regarding the role of statins among men electing AS.

To investigate this relationship further, we conducted a retrospective cohort study on men managed with AS from 2005-2015. The primary endpoints of analyses included the rate of disease reclassification, progression to definitive therapy, and surveillance failuredefined as a biochemical failure after definitive treatment, metastases, and prostate cancer-specific mortalityamong statin and non-statin users. Furthermore, we performed a logistic regression analysis in order to assess the impact of statin use on oncologic outcomes following definitive treatment.

635 patients were included in the study and 56.1% used statins at the initiation of AS. Statin users were older and had a longer median ...

News source: GOOGLE NEWS

See also: Associated Urologists Nashville